Open in PodwiseOpen

Podcast cover

BiotechTV · News

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Episodes

Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity

Get to know Women In Bio, and how this organization helps women at all stages of their careers in biotech

Emeryville, CA based Profusa is developing an injectable biosensor that aims to generate biochemistry information for users in real time

PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose

Benchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today

Benchtalk 2025: Generate:Biomedicines' VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models

Benchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D

Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial scheduled in DMD and DM1 over the next year

Sunrise Group, which has designed a mandibular sensor for at-home diagnosis of sleep apnea, recently raised $29M to expand its digital sleep clinic that patients can access remotely

Oxford's OrganOx became one of the UK's biggest news stories when it was announced it would be acquired by Japan's Terumo for approximately $1.5 billion - here's the revolutionary technology behind it

Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBF

NYSE Market Strategist Eric Criscuolo discusses biotech's newfound momentum and whether it might attract generalists to take a look at the sector

Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'

R.W. Baird Managing Director & Senior Biotech Analyst Brian Skorney discusses numerous battleground companies in biotech

Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio

Complement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye

Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including having programs in the red hot Nav1.7/1.8 pain space

Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6

Align Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM.

Soufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors

Page 12

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise